Last patient completed follow-up period in Phase II/III study of Amphera’s MesoPher cell therapy in mesothelioma

Topline results expected early Q4 2022 `S-HERTOGENBOSCH, Netherlands–(BUSINESS WIRE)–Amphera B.V., a late-stage biotechnology company developing cell therapies to treat cancer, announces that the last patient has completed the active follow-up in the Phase II/III DENIM study of MesoPher cell therapy to treat pleural mesothelioma. Ilona Enninga PhD, COO of Amphera said: “Despite the challenges experienced … [Read more…]

Differentiated Therapeutics Raises $5 Million Seed Round

Funding will accelerate development of novel disease-modifying targeted protein degraders against high value precision oncology targets SAN DIEGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Differentiated Therapeutics (dx/tx), a biotech company focused on computationally predicting and optimizing targeted protein degraders (TPDs), today announced the completion of a $5 million Seed financing. Curie.Bio, a founder-focused seed-stage venture capital firm, financed … [Read more…]

LENSAR to Report Second Quarter 2022 Financial Results on Monday, August 8, 2022

ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s second quarter 2022 financial results will be released before market open on Monday, August 8, 2022. LENSAR’s management will host a conference call … [Read more…]

New Cryo-Plasma Focused Ion Beam to Streamline Cellular Cryo-Electron Tomography Research

Thermo Scientific Arctis Cryo-Plasma FIB enables speed and consistency of cellular cryo-electron tomography HILLSBORO, Ore.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled the Thermo Scientific Arctis Cryo-Plasma Focused Ion Beam (Cryo-PFIB), a new connected and automated microscope designed to advance the pace of cryo-electron tomography (cryo-ET) research. Cryo-ET makes it … [Read more…]

Wejo and RoadMedic® Partner to Deliver RTTI™ Real-Time Traffic Data for Next-Generation 9-1-1 First Responders

Wejo RTTI™ will provide 9-1-1 first responders access to real-time comprehensive traffic data from millions of connected vehicles through Roadside Telematics Corp’s RoadMedic® Next-Generation 9-1-1 Intelligent Crash Data Ecosystem. MANCHESTER, England–(BUSINESS WIRE)–Wejo Group Limited (NASDAQ: WEJO), a global leader in Smart Mobility cloud and software solutions for connected, electric and autonomous vehicle data, today announced … [Read more…]

Covaris Appoints Annemarie Watson as Chief Executive Officer

WOBURN, Mass.–(BUSINESS WIRE)–Covaris, LLC (“Covaris” or “the Company”), a manufacturer of advanced tools enabling life science innovations, announced today that it has appointed Annemarie Watson as Chief Executive Officer, effective immediately. Ms. Watson succeeds Covaris founder Jim Laugharn, who will remain an investor in Covaris and on serve on the Company’s Board of Directors, as … [Read more…]

AVROBIO to Participate in Two Upcoming Investor Conferences in August

CAMBRIDGE, Mass.–(BUSINESS WIRE)–$AVRO—AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences: Hybrid BTIG Biotechnology Conference 2022 Dates: Monday, Aug. 8, 2022 – Tuesday, … [Read more…]

Shionogi Begins Phase 3 Study in Japan of Akili’s Digital Treatment in Children with ADHD

Pivotal study follows successful Phase 2 trial, which demonstrated improvements in attention function as compared to both treatment as usual and single task video game groups Pivotal Data Readout expected in 2H2023 BOSTON–(BUSINESS WIRE)–Akili Interactive (“Akili”), a leading digital medicine company, today announced the start of a pivotal Phase 3 randomized, controlled study of SDT-001 … [Read more…]

Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022

DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2022 and provide a business update on August 8, 2022. About Precision BioSciences, Inc. Precision BioSciences, Inc. … [Read more…]

Enanta Pharmaceuticals to Host Conference Call on August 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2022

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2022 after the U.S. market closes on August 8, 2022. Enanta management will host … [Read more…]